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Introduction
Multiple primary cancer (MPC) is a specific malignant tumor type,
manifesting as more than one primary tumor diagnosed in the same pa-
tient, either simultaneously or sequentially. The diagnostic criteria [1] in-
clude:  1)  the  cancer  must  be  clearly  malignant  as  determined  by
histological evaluation; 2) each cancer must be geographically separate
and distinct; 3) the possibility that the second tumor represents a metastasis
should be excluded. Synchronous multiple primary cancer (SMPC) is de-
fined as two or more tumors occurring within six months of each other,
while heterochronic multiple primary cancer is a subset of SMPC where
the second cancer occurs more than six months after the first. As previ-
ously reported [2], the major hematological conditions in patients with
multiple malignancies include multiple myeloma, myelodysplastic syn-
dromes, non-Hodgkin’s lymphoma, and chronic myelogenous leukemia
(CML). The major sites of MPC occurrence, sans hematological malig-
nancies, include the stomach, colon, breast, and esophagus. The incidence
of SMPC is very low, and it is even less common than synchronous pres-
entation of a solid tumor with a hematological malignancy. The mecha-
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The reported incidence of synchronous multiple primary cancer (SMPC) is rare, and it is even
less common to observe synchronous solid tumor with a hematological malignancy. We report
five cases of solid tumor presented synchronously with hematological malignancy, all observed
within a 2 year period at the oncology department of a university hospital in Shanghai, China.
These individual cases included lung adenocarcinoma with chronic myelogenous leukemia, colon
cancer with solitary plasmocytoma, gastric adenocarcinoma with diffuse large B cell non-
Hodgkin’s lymphoma, lung adenocarcinoma with multiple myeloma, and colon cancer with diffuse
large B cell non-Hodgkin’s lymphoma. It is challenging to therapeutically control the biological
behavior of concurrent multiple primary tumors, and there is no standard treatment for such rare
conditions. In this paper we discuss these five cases of SMPC and their treatments. 
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volved in MPCs may include tobacco and alcohol intake, infections and
immunosuppression, genetic predisposition, and toxic effects related to
treatment by chemotherapy or radiotherapy [2]. Herein, we report five
cases of synchronous solid tumor and hematological malignancy, and dis-
cuss the treatment of such rare malignancies. 
C ase  R epor t
From January 2008 to January 2010, five patients diagnosed with syn-
chronous solid tumor and hematological malignancy were admitted to
the medical oncology department at Zhongshan Hospital at Fudan Uni-
versity in Shanghai, China. The SMPC diagnosis for these five cases ac-
counted for 0.5% of all newly diagnosed cancerous patients during this
time period. The mean age of these patients was 53.8 years old and their
median survival time was 14.0 months (95% confidence interval, 6.12 to
21.88 months). The detailed clinical data is listed in Table 1.
1. Case 1
A 56-year-old female with a mass found at her right groin. The biopsy
pathology result for the mass indicated plasmablast myeloma. Immuno-
histochemistry assay revealed leukocyte common antigen (LCA, +++),
CD20(-), CD3(-), CD79ʱ (weak positive), CD45RO(-), plasmacyte an-
tibody(-), epithelial membrane antigen (weak positive), κ(+++), λ(-),
CD5(-), and CD10(-). The patient’s immunoglobins were observed to be
normal, and serum electrophoresis and immunoelectrophoresis showed
no M protein. Dysplastic plasma cells accounted for less than 5% of the
bone marrow aspirate and biopsy results. Isolated extramedullary plas-
macytoma (EMP) was diagnosed and she did not receive any therapeutic
treatment. At her six month follow-up visit, spiral computed tomography
(CT) scan revealed a lesion located in the right lung with hilar lymph node
enlargement. The patient received the video-assisted thoracoscopic sur-
gery (VATS) in radical operation for lung tumor.
The post-surgery pathology result revealed the lesion to be adenocar-
cinoma (pT2N0M0, stage IB) and the hilar lymph nodes to be negative.
Concurrent laboratory tests revealed a serum beta-2 microglobulin result
of 3.45 mg/L. The right groin mass remained palpable and had grown
larger. 
Elevated tumor markers were observed for  cancer antigen 125
(CA125, 86.8 IU/mL) and neuron-specific enolase (51.2 ng/mL). Because
the patient’s beta-2 microglobulin had increased, we chose to use vinorel-
bine as it is effective for treating myeloma [3,4]. The patient received 
vinorelbine plus cisplatin (NP) regimen (cisplatin 40 mg d1-3 plus vi-
norelbine 40 mg d1, d8, q21d) for four cycles. The right groin mass re-
duced in size after chemotherapy and the tumor marker decreased to a
normal level, at which point, 45 Gy radiotherapy was successfully deliv-
ered to the right groin. On the fifth month post-treatment follow-up, mul-
tiple masses were found in the bilateral lung. Percutaneous biopsy revealed
recurrent adenocarcinoma of the lung. Single agent pemetrexed at a dose
of 1,000 mg was administered to the patient for two cycles in keeping
with disease progression. This patient’s progression free survival duration
was three months and she died of respiratory failure at 22 months from
diagnosis.
2. Case 2
A 50-year-old male with cough and dyspnea which was aggravated by
movement. A malignant cell was found in his pleural effusion. A concur-
rent, routine blood test revealed total white blood cell (WBC) count of
116.20ￗ109/L, hemoglobin 132 g/L and granulocytes 45.3ￗ109/L. A color
Doppler abdominal ultrasound examination found splenomegaly. Various
immature granulocytes were observed in the peripheral blood smear. The
bone marrow aspirate assay uncovered active karyocyte hyperplasia, gran-
ulocyte/erythroid 61.7/1, active granulocyte hyperplasia, and granular left
shift with relatively restrained erythrocyte series hyperplasia. Neutrophil
alkaline phosphatase staining produced negative results and the bone mar-
row biopsy revealed granulocyte series neoplastic hyperplasia with
myeloperoxidase granulocyte(++), lysozyme granulocyte(+), CD34(+),
CD68 histiocyte(+), CD61 macronucleus(+), CD10(+), TdT(-), LCA par-
tial(+), CD20(-), CD3(-), and CD56(-). The sum of these results confirmed
a diagnosis of CML. The patient was orally administered hydroxyurea
for one week and his WBC counts decreased progressively after treatment
Table 1. Clinical data for five synchronous multiple primary cancerous patients
No. Gender Age One primary cancer Another primary cancer
(yr) Diagnosis Treatment Interval (mo) Diagnosis Treatment OS (mo)
1F 56 Myeloma -5 Lung cancer Ope+chemo 22
2M 50 CML Chemo 0.25 Lung cancer Chemo 14
3F 53 Colon cancer Ope 1 Lymphoma Chemo 7
4M 47 Colon cancer Chemo 0.5 Myeloma Chemo 4.5
5M 63 Gastric cancer Ope 0 Lymphoma Chemo 10
The intervals between two primary tumors were all less than six months. OS, overall survival; F, female; Ope, operation; Chemo, chemotherapy;
M, male; CML, chronic myelogenous leukemia.
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(WBC, 13.65ￗ109/L; granulocytes, 9.3ￗ109/L). Left pleura biopsy pathol-
ogy under VATS revealed adenocarcinoma. The tumor markers for
CA199, CA125 and CA153 in blood were 199.1 IU/mL, 114.9 IU/mL
and 103.9 IU/mL, respectively. A bone scan found multiple bone metas-
tases. He was diagnosed with non-small cell lung cancer (NSCLC) with
bone metastasis (stage IV). NP regimen (cisplatin 40 mg d1-3 plus vi-
norelbine 40 mg d1,8, q21d) was administered for six cycles, and the re-
sponse was partial remission. He was then shifted to a maintenance ther-
apy of gefitinib at a dose of 250 mg/day and zoledronic acid at a dose of
15 mg once/month. Two months later, the tumor marker was observed to
rise further and the bone metastasis progressed. Pemetrexed of 1,000 mg
dose was administered for three cycles as a second-line salvage therapy.
The disease continued to progress with metastasis to the brain and liver.
The patient’s post-diagnosis survival time was 14 months. 
Fig. 2. Case 4 pathological figures. (A) Computed tomography scan result identifying liver metastasis from colon cancer. (B) Computed tomography
scan identifying lung metastasis from colon cancer. (C) Colon adenocarcinoma revealed by colonoscopy (H&E staining, ￗ10). (D) Bone marrow
aspiration smear showing dysplastic plasma cells (Giemsa staining, ￗ10).
A B
C D
Fig. 1. Case 3 pathological figures. (A) Post surgery colon adenocarcinoma (H&E staining, ￗ40). (B) Biopsy result revealing lymphoma (H&E
staining, ￗ40).
A B
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3. Case 3
A 53-year-old female initially presented with several masses on the left
neck. A biopsy was performed and the pathological diagnosis was reactive
hyperplasia with mild dysplasia of the lymphoid tissue. It was a kind of
inflammatory reaction. The patient reported severe constipation in the
prior month, so a colonoscopy was performed which found a mass at the
sigmoid colon. After radical resection, the pathological diagnosis was mu-
cinous adenocarcinoma (pT3N0M0, stage II). Meanwhile, the left neck
masses progressively enlarged, and a biopsy confirmed diffuse large B
cell non-Hodgkin’s lymphoma with LCA(+), CD20(++), CD79ʱ(++),
CD3(partial positive), CD10(-), BCL-6(-), BCL-2(50%+), Ki-67(20%+),
MUM(-), CD68(+), CD4(partial positive), and CD8(+), as illustrated in
Fig. 1. After two cycles of R-CHOP (rituximab 600 mg d0, cyclophos-
phamide 1.0 d1, epirubicin 80 mg d1, vindesine 4 mg d1 plus methyl-
prednisolone 80 mg d1-5, q21d), the patient attained complete remission.
Two additional cycles of R-CHOP were administered. The patient sur-
vived until the final, scheduled follow-up visit. Her survival duration was
seven months from time of diagnosis.
4. Case 4
A 47-year-old male with a liver mass was found in conjunction with a
report of weight loss during a routine health examination. A colonoscopy
found adenocarcinoma at the cecum, and his blood test revealed a WBC
count of 2.60ￗ109/L, hemoglobin of 78 g/L, and platelet count of
121ￗ109/L. A CT scan found metastasis of the lung and liver, and his car-
cinoembryonic antigen elevated to 601.0 ng/mL. He was diagnosed with
stage IV colon cancer. Concurrent serum electrophoresis and immuno-
electrophoresis revealed abnormal kappa light chain. The bone marrow
aspirate and biopsy demonstrated more than 25% dysplastic plasma cells,
as seen in Fig. 2. The patient’s serum beta-2 microglobulin was 12.83
mg/L. A plain skeletal X-ray revealed multiple lytic bony lesions (MM,
stage III). He was treated with dexamethasone 40 mg d1-4, d9-12, adri-
amycin 15 mg d1-4, plus capecitabine 1,500 mg bid d1-14. After two cy-
cles, the serum beta-2 microglobulin and kappa light chain reduced.
However, the patient succumbed to the progressing lung and liver metas-
tasis from the colon cancer, with survival duration of 4.5 months from
time of diagnosis.
Fig. 3. Case 5 pathological figures. (A) biopsy result revealing lymphoma in right upper abdominal mass (H&E staining, ￗ40). (B) Gastric ade-
nocarcinoma identified after radical subtotal gastrectomy (H&E staining, ￗ40). F18-FDG high uptake lesion at gastric sinus (C) and right upper
abdomen (D), as observed by positron emission tomography/computed tomography).
A B
C D
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5. Case 5
A 63-year-old male with an uneven mass found in his right upper ab-
domen by ultrasound during a routine medical examination. Gastroscopy
revealed low-grade differential adenocarcinoma on the gastric angle. Per-
cutaneous biopsy of the right upper abdomen mass verified diffuse large
B cell non-Hodgkin’s lymphoma, with cytokeratin (CK)(-), CK19(-),
CD45 (LCA, +++), CD20(+++), CD3(±), CD30 (-), CD79ʱ(++), and
CD45RO(+), as seen in Fig. 3. A therapeutic regimen was administered
including rituximab 600 mg d0, etoposide 100 mg d1-3, epirubicin 40
mg d1-2, cisplatin 30 mg d1-3, and methylprednisolone 40 mg d1-4 plus
vincristine 1 mg d1. After two cycles, the abdominal mass disappeared
and the mass in the stomach appeared stable as observed by ultrasonic
gastroscopy. Because the patient complained of anorexia and weight loss,
after discussion of alternatives and indications, he received radical subtotal
gastrectomy (pT3N1M0). Administration of one cycle of rituximab 600
mg d0, epirubicin 40 mg d1-2, cisplatin 30 mg d1-3, and methylpred-
nisolone 40 mg d1-4 plus vincristine 2 mg d1, was delivered after surgery.
At his follow-up hospital visit, a mass was found in his right upper ab-
domen during CT scan. He then received a second-line R-ICE chemother-
apy regimen (rituximab 600 mg d0, ifosfamide 2.0 d1-4, and carboplatin
150 mg d1-3 plus etoposide 150 mg d1-3) for three cycles. The result was
complete remission. Two months later, the patient suffered vomiting from
intestinal obstruction. Because his symptoms couldn’t be relieved by con-
servative treatment, an exploratory laparotomy was performed which dis-
covered peritoneal metastasis from gastric cancer. The pathology of the
small peritoneal metastatic lesions revealed adenocarcinoma. The patient’s
performance status deteriorated after surgery and his survival duration
from time of diagnosis was 10 months.
Discussion
The precise mechanism of SMPC has remained unknown and there
are no uniform treatment guidelines. Recent studies have demonstrated
evidence of a possible spread of cancerous cells from a single clone to
multiple sites [5,6]. It was reported whether or not genetic defects involv-
ing the mismatch repair system constituted an important risk factor in pa-
tients with MPC [7]. An Argentine research group found 32% of MPC
patients had a family history of oncologic diseases [8]. In this report, we
found only one patient (case 5, accounting for 20%) who carried this ge-
netic tendency. Both his father and uncle had died from cancer.
A literature review of 1,104,269 cancer patients concluded that the
prevalence of MPC is between 0.73% and 11.7% [9]. The wide variation
in reporting was concluded to be associated with the varying capabilities
and experience of hospitals and their doctors. At our one hospital we re-
ceived five SMPC patients in a relatively short time, and it reminded us
to carefully consider the appearance of such diseases. In these cases, there
is a change not only in disease spectrum, but also the cancer spectrum.
With increased availability of methods with greater sensitivity for screen-
ing organs susceptible to MPCs, there may be an increase of frequency in
the identification of multiple primaries in the coming years.
Although it is both impractical and unnecessary to obtain biopsies for
every metastatic lesion that may appear in a case of MPC, awareness of
the different biological behaviors between solid tumors and hematologic
malignancies should be considered. In this report, some patients came to
the hospital presenting solid tumors symptoms, and others for hematologic
malignancies. But some symptoms couldn’t be controlled effectively
while treating a single tumor, and other lesions appeared to defy the routine
metastatic rule. These clinical observations should remind us to investigate
the possibility of SMPC. A re-biopsy is the only way to verify suspicion
of SMPC. Published literature has reported that such diseases are often
located at the same organ, such as simultaneous Hodgkin’s lymphoma
and adenosquamous carcinoma in the uterine cervix, and adenocarcinoma
and lymphoma in the stomach [10-12].
Lacking guidelines in the management of such diseases, the treatment
modality should be determined using the doctor experience and close at-
tention to the characteristics of the patient’s illness and performance status.
The EMP in case 1 was early stage with good prognosis, so therapy was
not delivered as it was not expected to affect patient survival time. We
chose the NP regimen instead of gemcitabine plus cisplatin or paclitaxel
plus cisplatin, because vinorelbine is a kind of vinca alkaloid drug, and
the regimen is appropriate to both lung cancer and plasmatic disease. Be-
cause epidermal growth factor receptor (EGFR) mutation status was not
detected, pemetrexed instead of gefitinib was chosen as the second-line
chemotherapy. In case 2, the patient’s WBC count decreased rapidly after
just one week of hydroxyurea treatment, but the patient did not recover
from the dyspnea symptoms. This raised the suspicion that another pri-
mary cancer was involved, which was revealed by VATS to be lung can-
cer. Because CML and lung cancer were found at the same time,
hydroxyuria was chosen for its effectiveness in reducing WBC counts
rapidly. Because the CML was controlled well and had little effect on
long-term survival, the patient received six cycles of NP regimen and gefi-
tinib maintenance therapy. During treatment for NSCLC, the patient did
not receive any therapy for CML because routine blood tests were normal.
The initial diagnosis for case 3 was lymphoid tissue reactive hyperplasia
of the neck, but then, sigmoid colon cancer was found and a radical re-
section was administered. After the operation, the left neck mass enlarged.
This observation triggered the biopsy to be repeated and lead to a diagnosis
of lymphoma. As the pair of tumors were both early stage, the patient had
a good prognosis with a long survival time. The case 4 patient presented
two severe tumors, MM (stage III) and colon cancer (stage IV). Choosing
a proper regimen was difficult because both the WBC and hemoglobin
counts were low. We treated the MM mainly with dexamethasone and
adriamycin, and controlled the colon cancer using low dose intensity
capecitabine in hopes that the blood test results would improve. Then, we
administered the standard chemotherapy to treat the advanced colon can-
cer, but the disease had progressed too quickly. Simultaneous abdominal
lymphoma and gastric cancer were found in case 5. Because the abdom-
inal lymphoma was extensive, the treatment regimen followed the lym-
phoma guideline. Consideration was also made for the gastric cancer.
Cyclophosphamide was displaced by cisplatin in the regimen.
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R efer ences
After the lymphoma was satisfactorily controlled, only then was the
gastric cancer operated on. After the operation, two lymph nodes of twenty
remained. Unfortunately the tumors were not early stage and overall sur-
vival time was short.
SMPCs are difficult to deal with because clinicians might not be able
to provide simultaneous treatment for both disease types, such as one treat-
ment resulting in competing toxicities for treating the other. The treatment
choice depends on the tumor location and may involve curative surgical
resection of each cancer, radiotherapy, and chemotherapy [13,14]. Our
main approach to treating SMPCs was to abide by the therapeutic princi-
ples associated with each tumor and to consider both when treating one
of the malignant diseases. We recommend that doctors formulate indi-
vidual therapeutic strategies according to the patient’s illness. The thera-
peutic effects and patient endurance must be evaluated at the same time.
Case discussion with a multiple-disciplinary team may be helpful.
According to the literature, the prognosis of MPC patients can be de-
termined independently as a function of the stage of each cancer. We found
that the SMPC prognosis would be good if the tumors were all at early
stage, otherwise the prognosis was likely poor. When the tumors are ad-
vanced stage at diagnosis, it is always a question of whether this is due to
a delay in diagnosis or dependent on the biology of the tumor, such as a
high grade tumor, etc. As a summarizing thought to consider, when en-
countering SMPCs, the fewer reported cases available to reference makes
treatment that much more of a challenge. 
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